Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting

ROCKVILLE,M.D. and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2022-11-14 08:00 4619

Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

ROCKVILLE, M.D. and SUZHOU, China, Nov 7, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2022-11-07 08:00 4757

Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors

ROCKVILLE, Md. and SUZHOU, China, Oct. 30, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2022-10-31 08:00 4246

Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine

ROCKVILLE, Md. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2022-10-17 08:00 5056

The China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2022-10-10 08:23 4356

The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma

ROCKVILLE, Md. and SUZHOU, China, Oct. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2022-10-10 08:20 3899

Innovent's Sintilimab plus Chemotherapy Demonstrated PFS Benefit in Patients with EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Second Interim Analysis Results of the ORIENT-31 Study

ROCKVILLE, Md. and SUZHOU, China, Sept. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven...

2022-09-08 08:05 4814

Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

ROCKVILLE, Md. and SUZHOU, China, Sept. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2022-09-05 08:00 4307

Innovent Announced 2022 Interim Results and Business Updates

* Leading the Way in Developing a More Sustainable Business Model for Innovative Biopharmaceutica...

2022-08-25 20:06 7084

Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

ROCKVILLE, Md. and SUZHOU, China, Aug. 23, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2022-08-24 08:00 4728

Innovent Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)

SAN FRANCISCO and SUZHOU, China, Aug. 18, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-08-18 08:00 4483

Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint

SAN FRANCISCO and SUZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-08-10 08:00 4649

Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema

SAN FRANCISCO and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2022-08-08 08:00 4017

Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China

* Collaboration to accelerate the development and access of oncology medicines for cancer patient...

2022-08-04 23:30 5658

Innovent and Laekna Jointly Announce First Patient Dosed with Three-drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy

SAN FRANCISCO and SUZHOU, China, Aug. 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2022-08-01 08:00 3829

Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML

SAN FRANCISCO, ROCKVILLE, Md. and SUZHOU, China, July 20, 2022 /PRNewswire/ -- Innovent Biologics, ...

2022-07-20 08:00 3954

Significant Glycemic Control and Weight Loss: Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint

SAN FRANCISCO and SUZHOU, China, July 19, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2022-07-19 08:00 5218

Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis

SAN FRANCISCO and SUZHOU, China, July 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2022-07-04 08:00 4177

Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications

SAN FRANCISCO and SUZHOU, China, June 29, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-06-29 08:00 3996

Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, June 27, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-06-27 08:00 5048